Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back

NCT ID: NCT00671879

Last Updated: 2012-11-21

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

830 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-04-30

Study Completion Date

2009-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine if two sustained released formulations of carisoprodol are more effective than placebo.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Methodology:

This will be a randomized, double-blind, double-dummy, placebo-controlled, parallel-group study in subjects 18-70 years of age with acute, painful, muscle spasm of the lower back. The study consists of a baseline screening (Study Day 1), during which subjects will be evaluated for inclusion/exclusion criteria, and a 7-day double-blind treatment period (Study Day 1 through Study Day 7). Subjects will be randomly assigned to be dosed twice daily with one of the following double-blind treatments: SR carisoprodol 500-mg tablets, SR carisoprodol 700-mg tablets, or placebo.

Subjects will be evaluated in the clinic on Study Days 1, 3 and 7. Subjects who remain symptomatic on Study Day 7 will be allowed to continue in the study for a 7-day, double-blind extension period at the discretion of the Investigator. Subjects will be contacted by telephone for a safety follow-up 7 days after the last dose of study medication.

A pharmacokinetic (PK) substudy will be conducted at selected sites. These sites will obtain blood samples for PK analysis at the end of the 7-day treatment period and the 14-day treatment period, if applicable.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lower Back Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Carisprodol SR 700 mg

Carisoprodol 700 mg twice daily

Group Type EXPERIMENTAL

Carisoprodol SR 700 mg

Intervention Type DRUG

700 mg twice daily tablet

Carisoprodol SR 500mg

Carisoprodol SR 500 mg twice daily

Group Type EXPERIMENTAL

Carisoprodol SR 500 mg

Intervention Type DRUG

carisoprodol SR 500 mg tablet

Placebo

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

placebo tablet

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Carisoprodol SR 700 mg

700 mg twice daily tablet

Intervention Type DRUG

Carisoprodol SR 500 mg

carisoprodol SR 500 mg tablet

Intervention Type DRUG

Placebo

placebo tablet

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

no other name no other name no other name

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Onset of pain is within 3 days of first visit
* Subject rating of pain must be 40 mm or greater on VAS
* Ability to discontinue all analgesics, NSAIDs, and other muscle relaxants
* Willingness to provide written informed consent
* Must be in generally good health

Exclusion Criteria

* Presence of sciatic pain
* History of clinically significant spine pathology such as herniated nucleus pulpous, spondylolisthesis, spinal stenosis
* Presence of underlying chronic back pain
* Neurological signs and symptoms such as numbness, tingling, foot drop, paresthesia, unexplained constipation, urinary retention or urinary incontinence
* Myocardial infarction within one year of study
* Cancer not in remission or in remission less than one year
* HIV or other immunodeficiency syndromes
* History of osteoporosis or at high risk for vertebral fracture
* Underlying rheumatologic disease such as rheumatoid arthritis, ankylosing spondylitis, etc.
* Presence of active influenza or other viral syndromes
* Morbid obesity (BMI \>39)
* Evidence of infection, such as low grade fever or neutrophilia
* Existence of any medical/surgical condition that could interfere with the evaluation of the study medication
* Known history of alcohol or drug abuse
* Injury involving high potential for litigation, including worker's compensation or automobile accidents
* Pregnancy or breast feeding
* Women of child-bearing potential not abstinent or not practicing a medically acceptable method of contraception
* Vertebral body or spinous process, percussive tenderness on physical exam
* Any abnormalities in the following tests of both lower extremities: ankle dorsiflexion strength, great toe dorsiflexion strength, absent or hyperreflexic Achilles or patellar tendor reflexes, abnormal sensory exam in the medial, dorsal or lateral aspect of the foot and positive straight leg raise test
* Urgent medical conditions on comprehensive exam that might indicate a more serious condition should be treated urgently
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Meda Pharmaceuticals

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Lewis M. Fredane, MD

Role: STUDY_DIRECTOR

Meda Pharmaceuticals

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Brookwood Internists, P.C.

Birmingham, Alabama, United States

Site Status

Gulf Shores General Practice Center

Gulf Shores, Alabama, United States

Site Status

Simon Williamson Clinic, PC

Hueytown, Alabama, United States

Site Status

Vaugh H Mancha Jr., PC Family Practice

Montgomery, Alabama, United States

Site Status

NextCare Institute for Clinical Research

Phoenix, Arizona, United States

Site Status

HOPE Research Institute

Phoenix, Arizona, United States

Site Status

Fiel Family and Sports Medicine

Tempe, Arizona, United States

Site Status

Lynn Institute of the Ozarks

Little Rock, Arkansas, United States

Site Status

Quality of life Medical, LLC

Anaheim, California, United States

Site Status

ICT - Beverly Hills

Beverly Hills, California, United States

Site Status

Lovelace Scientific Resources, Inc.

Burbank, California, United States

Site Status

Chrishard Medical Group

Inglewood, California, United States

Site Status

Impact Clinical Trials and Powerplay

Los Angeles, California, United States

Site Status

Newport Beach Clinical Research Associates, Inc.

Newport Beach, California, United States

Site Status

San Diego Managed Care Group

San Diego, California, United States

Site Status

Crest Clinical Trials, Inc.

Santa Ana, California, United States

Site Status

Santa Barbara Clinical Research Inc.

Santa Barbara, California, United States

Site Status

Clinicos, LLC

Colorado Springs, Colorado, United States

Site Status

Horizons Clinical Research Center, LLC

Denver, Colorado, United States

Site Status

Tampa Bay Medical Research

Clearwater, Florida, United States

Site Status

Atlantic Institute of Clinical Research

Daytona Beach, Florida, United States

Site Status

Florida Research Network, LLC

Gainesville, Florida, United States

Site Status

Orthopaedic Assoc. of S. Broward, P.A.

Hollywood, Florida, United States

Site Status

FPA Clinical Research

Kissimmee, Florida, United States

Site Status

Jay Care Medical Center

Lakeland, Florida, United States

Site Status

Innovative Research of West FL, Inc.

Largo, Florida, United States

Site Status

Oslar Medical, Inc./ Osler Clinical Research

Melbourne, Florida, United States

Site Status

Homestead Clinical Research

Naranja, Florida, United States

Site Status

Andres Patron, DO, PA

Pembroke Pines, Florida, United States

Site Status

Wilker/Powers Center for Clinical Studies

Saint Cloud, Florida, United States

Site Status

Orlando Rangel, M.D., P.A.

Tampa, Florida, United States

Site Status

West Wind'r Research & Development, LLC

Tampa, Florida, United States

Site Status

Palm Beach Research center

West Palm Beach, Florida, United States

Site Status

PMI Health Research Group

Atlanta, Georgia, United States

Site Status

Perimeter Institute for Clinical Research, Inc.

Atlanta, Georgia, United States

Site Status

Best Clinical Research

Decatur, Georgia, United States

Site Status

Dupage Family Medicine

Naperville, Illinois, United States

Site Status

Heartland Research Associates, LLC

Wichita, Kansas, United States

Site Status

Bluegrass Orthopaedics & Hand Care Research

Lexington, Kentucky, United States

Site Status

Central Kentucky Research Associates, Inc.

Lexington, Kentucky, United States

Site Status

Clinical Research Institute

New Orleans, Louisiana, United States

Site Status

Highland Clinic, APMC

Shreveport, Louisiana, United States

Site Status

Waterford Medical Associates

Waterford, Michigan, United States

Site Status

CRC of Jackson

Jackson, Mississippi, United States

Site Status

Quality Clinical Research, Inc.

Omaha, Nebraska, United States

Site Status

Dr. Meera Dewan PC

Omaha, Nebraska, United States

Site Status

Association of International Professionals

Las Vegas, Nevada, United States

Site Status

ICT - Las Vegas

Las Vegas, Nevada, United States

Site Status

Immedicenter

Bloomfield, New Jersey, United States

Site Status

Land Clinical Studies

West Caldwell, New Jersey, United States

Site Status

Research Across America

New York, New York, United States

Site Status

Odyssey Research

Fargo, North Dakota, United States

Site Status

Parsons Avenue Medical Clinic

Columbus, Ohio, United States

Site Status

Dayton Clinical Research

Dayton, Ohio, United States

Site Status

Hillcrest Clinical Research

Oklahoma City, Oklahoma, United States

Site Status

Harleysville Medical Associates

Harleysville, Pennsylvania, United States

Site Status

Warminster Medical Association

Warminster, Pennsylvania, United States

Site Status

DeGarmo Institute of Medical Research

Greer, South Carolina, United States

Site Status

Palmetto Family Medicine Center

Pelzer, South Carolina, United States

Site Status

Holston Medical Group, P.C.

Kingsport, Tennessee, United States

Site Status

Medical Clinic of North Texas

Arlington, Texas, United States

Site Status

Central Texas Clinical Research

Austin, Texas, United States

Site Status

DiscoveResearch, Inc.

Bryan, Texas, United States

Site Status

Texas Family Care Clinical Research

Colleyville, Texas, United States

Site Status

Research Across America

Dallas, Texas, United States

Site Status

Georgetown Medical Clinic

Georgetown, Texas, United States

Site Status

F. Adam Kawley, MD PA

Houston, Texas, United States

Site Status

Central Texas Health Research

New Braunfels, Texas, United States

Site Status

GSA Research

San Antonio, Texas, United States

Site Status

Sun Research Institute

San Antonio, Texas, United States

Site Status

Sylvana Research Associates

San Antonio, Texas, United States

Site Status

Clinical Health Research, LLC

Sugar Land, Texas, United States

Site Status

Holston Medical Group, P.C.

Weber City, Virginia, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MP511

Identifier Type: -

Identifier Source: org_study_id